Novo Nordisk A/S

06/23/2024 | Press release | Archived content

Novo Nordisk A/S: Mim8 demonstrated superior reductions in annualised bleeding rate (ABR) compared to on-demand and prior prophylaxis treatment in people with haemophilia A